Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
Ko Un Park(The Ohio State University Wexner Medical Center), Alastair M. Thompson(Baylor College of Medicine), Megan E. Gregory(University of Florida Health), Ann H. Partridge(Dana-Farber Cancer Institute), Priyanka Sharma(Chandigarh University), Chengli Shen(The Ohio State University Wexner Medical Center), J.G. Bazan(The Ohio State University Wexner Medical Center), Victoria Blinder(Memorial Sloan Kettering Cancer Center), Lajos Pusztai(Yale University), Maryam B. Lustberg(Yale Cancer Center), Shoshana M. Rosenberg(Dana-Farber Cancer Institute)
Cited by 41
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k